Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Acrivon Therapeutics, Inc. (ACRV)
NASDAQ:ACRV
Holding ACRV?
Track your performance easily
ACRV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.19 - $11.90
Previous CloseN/A
Volume1.72K
Average Volume (3M)49.26K
Market Cap
$169.69M
Enterprise Value$83.30M
Total Cash (Recent Filing)$1.58M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Mar 26, 2025EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.70
Shares Outstanding31,136,295
10 Day Avg. Volume35,892
30 Day Avg. Volume49,256
Standard Deviation0.26
R-Squared0.01
Alpha-0.00894
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1266.36
Price to Cash Flow (P/CF)-2.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.49
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit621.61
Enterprise Value/Ebitda-1.06
Forecast
1Y Price Target
$21.67Price Target Upside290.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Acrivon Therapeutics, Inc. News
Bulls Say, Bears Say
Bulls Say
Clinical Development ProgressAcrivon completed the planned enrollment of the first dose-escalation cohort in the Phase 1 trial with the PKMYT1/WEE1 dual inhibitor ACR-2316, indicating progress in clinical development.
Efficacy Of ACR-368Acrivon's data in endometrial cancer continue to show positive results, with ACR-368 monotherapy achieving an ORR of 63% in Oncosig/BM+ patients.
Financial StabilityThe company has reiterated a cash runway into the second half of 2026, reflecting strong financial stability.
Bears Say
Approval ChallengesThe BM+ population which would likely be used for accelerated approval is still small, and significantly more patients would be needed to support approval.
Clinical Trial ChallengesThe OncoSig negative (BM-) endometrial cancer patients showed low response rates, leading to uncertainty about the path forward in this cohort.
Drug Efficacy ConcernsThe program was in-licensed from Lilly following a failure to meet target efficacy levels of 30%-40%.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ACRV FAQ
What was Acrivon Therapeutics, Inc.’s price range in the past 12 months?
Acrivon Therapeutics, Inc. lowest stock price was $3.19 and its highest was $11.90 in the past 12 months.
What is Acrivon Therapeutics, Inc.’s market cap?
Acrivon Therapeutics, Inc.’s market cap is $169.69M.
When is Acrivon Therapeutics, Inc.’s upcoming earnings report date?
Acrivon Therapeutics, Inc.’s upcoming earnings report date is Mar 26, 2025 which is in 54 days.
How were Acrivon Therapeutics, Inc.’s earnings last quarter?
Acrivon Therapeutics, Inc. released its earnings results on Nov 13, 2024. The company reported -$0.59 earnings per share for the quarter, missing the consensus estimate of -$0.578 by -$0.012.
Is Acrivon Therapeutics, Inc. overvalued?
According to Wall Street analysts Acrivon Therapeutics, Inc.’s price is currently Undervalued.
Does Acrivon Therapeutics, Inc. pay dividends?
Acrivon Therapeutics, Inc. does not currently pay dividends.
What is Acrivon Therapeutics, Inc.’s EPS estimate?
Acrivon Therapeutics, Inc.’s EPS estimate is -0.66.
How many shares outstanding does Acrivon Therapeutics, Inc. have?
Acrivon Therapeutics, Inc. has 31,136,295 shares outstanding.
What happened to Acrivon Therapeutics, Inc.’s price movement after its last earnings report?
Acrivon Therapeutics, Inc. reported an EPS of -$0.59 in its last earnings report, missing expectations of -$0.578. Following the earnings report the stock price went down -5.483%.
Which hedge fund is a major shareholder of Acrivon Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ACRV
---
Acrivon Therapeutics, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.67 (290.45% Upside)
$21.67 (290.45% Upside)
Blogger Sentiment
Bullish
ACRV Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.0%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
35.23%
12-Months-Change
Fundamentals
Return on Equity
-45.95%
Trailing 12-Months
Asset Growth
42.09%
Trailing 12-Months
Company Description
Acrivon Therapeutics, Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Company matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
---
ACRV Stock 12 Month Forecast
Average Price Target
$21.67
▲(290.45% Upside)
Technical Analysis
Alnylam Pharma
―
Ionis Pharmaceuticals
―
Sarepta Therapeutics
―
Bluebird Bio
―
Blueprint Medicines
―
Best Analysts Covering ACRV
1 Year
1 Year Success Rate
2/8 ratings generated profit
1 Year Average Return
-11.33%
reiterated a buy rating 3 months ago
Copying Etzer Darout's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -11.33% per trade.
---